ReviewNature reviews. Clinical oncology2025
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions.
Review in Nature reviews. Clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study.Cancer immunology, immunotherapy : CII · 2026Trial
- Application of artificial intelligence in head and neck squamous cell carcinoma.Annals of medicine · 2026Review
- Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone in stage IIIB-IV squamous non-small cell lung cancer: a systematic review and meta-analysis of phase 3 randomized controlled trials.Translational cancer research · 2026Article
- Integrated pan-cancer analysis reveals a cancer-associated fibroblast oxidative stress response signature predicting immunotherapy response and prognosis.Apoptosis : an international journal on programmed cell death · 2026Article
- GNL3L-LMNB1 signaling axis promotes lung squamous cell carcinoma growth and ferroptosis resistance via NF-κB activation.Journal of thoracic disease · 2026Article
- Cancer Vaccine Strategies in Non-Small Cell Lung Cancer.Vaccines · 2026Review
- Article
- cPLA2α inhibition potentiates anti-PD-1 immunotherapy in lung adenocarcinoma via remodeling tumor microenvironment.Communications biology · 2026Article
- Explainable AI reveals squamous histology and U-shaped PD-L1 patterns as primary subgroup predictors of neoadjuvant and perioperative immunotherapy benefit in NSCLC: a machine learning analysis.Cancer immunology, immunotherapy : CII · 2026Article
- Innovative approaches for lung cancer screening and interception.Nature reviews. Clinical oncology · 2026Review
- A monocyte-centered framework for predicting immunochemotherapy efficacy in lung squamous cell carcinoma patients.EMBO molecular medicine · 2026Article
- Current and future immunotherapies for NSCLC.Journal of hematology & oncology · 2026Review
- CAR immune cell therapy strategies and advances for lung cancer.Discover oncology · 2026Review
- Clinician-deployable deep hypergraph model integrating clinical and CT radiomics predicts immunotherapy outcomes in NSCLC.PLOS digital health · 2026Article
- PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy.Redox biology · 2026Article
- miR-3913-3p promoted the progression of lung adenocarcinoma by regulating STX3 expression.Hereditas · 2026Article
- An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins.JAMA network open · 2026Article
- Efficacy and safety of nab-paclitaxel plus PD-1 inhibitor in elderly patients with advanced squamous lung cancer.BMC cancer · 2026Article
- Microwave ablation combined with dendritic cells enhances CD8Cancer immunology, immunotherapy : CII · 2026Article
- ΔNp63α drives serine synthesis to promote carboplatin resistance in NSCLC.Cell death & disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced-stage squamous non-small-cell lung cancer (LUSC), a histological subtype associated with inferior outcomes compared with lung adenocarcinoma. However, only a subset of patients derive durable clinical benefit. In the first-line setting, multiple ICI regimens are available, including anti-PD-(L)1 antibodies as monotherapy, in combination with chemotherapy, or with an anti-CTLA4 antibody with or without chemotherapy. Several important questions persist regarding the optimal regimen for individual patients, particularly how to identify patients who might benefit from adding chemotherapy and/or anti-CTLA4 antibodies to anti-PD-(L)1 antibodies. An urgent need exists for predictive biomarkers beyond PD-L1 to better guide precision oncology approaches. Deeper knowledge of the underlying molecular biology of LUSC and its implications for response to ICIs will be important in this regard. Integration of this knowledge into multi-omics methods coupled with artificial intelligence might enable the development of more robust biomarkers. Finally, several novel therapeutic strategies, including novel ICIs, bispecific antibodies and personalized cancer vaccines, are emerging. Addressing these unresolved questions through innovative clinical trials and translational research will be crucial to further improving the outcomes of patients with LUSC. In this Review, we provide a comprehensive overview of current immunotherapeutic approaches, unresolved challenges and emerging strategies for patients with LUSC.
Indexed as
Identifiers
39762577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.